DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC
Clinical trial NCT00496652 · COMPLETED
Trial details
- NCT number
- NCT00496652
- Sponsor
- Danish Head and Neck Cancer Group
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2007-11-01
- Primary completion
- 2012-07-01
- Enrollment
- 619
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.